Menu
Our global networks and database form a key part of how we advise our clients to access markets, optimise price
points and communicate the true value of their asset.
MAXConnect is our global Payer and KOL network, hand-selected advice tailored to your situation.
MAXConnect is also a strategic guide to enable more effective PRMA decision-making for orphan drugs & ATMPs.
Whether you prefer one-to-one in-depth discussions, ad-boards, or online surveys, you’re covered with MAXConnect.
Introducing XINTA, P4A’s extensive global database of Orphan Drugs, Cell and Gene Therapy analogues.
Combined with P4A’s expertise in the space, we provide a premium bespoke service that delivers quality and agility.
XINTA analyses and interprets key learnings from analogue recommendations bespoke to your specific situation.
P4A hand-selected disease-specific P&C Councils help you learn from patients and caregivers through launch.
Despite unmet need, there are many patient-specific challenges in developing sustainable therapies for rare diseases.
Through engagements, clients acquire vital guidance throughout a product lifecycle; assets evolve alongside disease landscapes
